Physiomics to present and exhibit at SITC Annual Meeting
Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it is participating in the 37th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”), being held this week on 8-12 November 2022 in Boston, USA.
The Company will be presenting an original poster entitled: “Establishing the preclinical PKPD relationship for NM32-2668 a ROR1 targeting T cell engager”. Physiomics is co-authoring the poster with client Numab Therapeutics (“Numab”) whose investigational drug NM32 is currently in IND-enabling studies. NM32 is a tri-specific anti-ROR1/CD3/HSA antibody based on Numab’s scMATCH3 format which induces T cell-mediated lysis of tumours expressing Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1).
The pharmacokinetic and pharcodynamic models developed during this work provide quantitative confirmation of the mechanism of action of NM32-2668. The model will support the establishment of a first-in-human starting dose and a strategy to enable clinical effective dose selection.
The poster (Abstract #1293) will be presented on 10 November from 0900-1900 EST, with the presenting authors attending at lunch (1140-1310) and during the poster reception (1930–2100). The abstract is now available in Journal for ImmunoTherapy of Cancer’s November 2022 Issue Supplement, which can be accessed at: https://jitc.bmj.com/content/10/Suppl_2/A1341. A copy of the poster will be posted on Physiomics’ website at 0900 EST (1400 GMT) on the same day at: https://www.physiomics.co.uk/resources.
The Company will have substantial presence at the conference comprising both scientific and business development team members and will also host a stand in the main conference meeting hall (booth #236). If you’d like to meet the team at our booth please drop by or use this link to book a meeting: https://www.physiomics.co.uk/sitc-2022/.
SITC is the world’s leading member society of medical professionals dedicated to advancing cancer immunotherapy and biological therapy through its initiatives, educational sessions, and collaborative endeavours. More information about the conference may be found using the following link: https://www.sitcancer.org/2022/home.
Dr Jim Millen, CEO said: “It’s great to be able to attend high profile conferences such as SITC in person again, and a privilege to be presenting important new work there. The team and I look forward for our meetings with existing clients attending SITC as well as potential new clients based in the Boston area.”
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company’s Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics’ technologies have been confirmed by over 90 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.